These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 17460704)
41. Rare-event analysis in flow cytometry. Donnenberg AD; Donnenberg VS Clin Lab Med; 2007 Sep; 27(3):627-52, viii. PubMed ID: 17658410 [TBL] [Abstract][Full Text] [Related]
42. Natural killer function in flow cytometry: identification of human lymphoid subsets able to bind to the NK sensitive target K562. Vitale M; Zamai L; Neri LM; Manzoli L; Facchini A; Papa S Cytometry; 1991; 12(8):717-22. PubMed ID: 1838975 [TBL] [Abstract][Full Text] [Related]
43. Flow cytometric analysis of lymphomas and lymphoproliferative disorders. Stetler-Stevenson M; Braylan RC Semin Hematol; 2001 Apr; 38(2):111-23. PubMed ID: 11309693 [TBL] [Abstract][Full Text] [Related]
45. Setting up and calibration of a flow cytometer for multicolor immunophenotyping. Kraan J; Gratama JW; Keeney M; D'Hautcourt JL J Biol Regul Homeost Agents; 2003; 17(3):223-33. PubMed ID: 14524607 [No Abstract] [Full Text] [Related]
46. Flow cytometric immunophenotyping of plasmacytic neoplasms. DiGiuseppe JA Am J Clin Pathol; 2007 Feb; 127(2):172-4. PubMed ID: 17210527 [No Abstract] [Full Text] [Related]
47. A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders. Pedreira CE; Costa ES; Almeida J; Fernandez C; Quijano S; Flores J; Barrena S; Lecrevisse Q; Van Dongen JJ; Orfao A; Cytometry A; 2008 Dec; 73A(12):1141-50. PubMed ID: 18836994 [TBL] [Abstract][Full Text] [Related]
48. Optimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow. Jones EA; English A; Kinsey SE; Straszynski L; Emery P; Ponchel F; McGonagle D Cytometry B Clin Cytom; 2006 Nov; 70(6):391-9. PubMed ID: 16977637 [TBL] [Abstract][Full Text] [Related]
49. A practical approach to the flow cytometric detection and diagnosis of T-cell lymphoproliferative disorders. Meyerson HJ Lab Hematol; 2010 Sep; 16(3):32-52. PubMed ID: 20858587 [TBL] [Abstract][Full Text] [Related]
54. Evolving progress in the management of malignant plasma cell disorders. Atilgan E; Gonsalves WI Cancer Treat Res Commun; 2022; 32():100612. PubMed ID: 35872008 [No Abstract] [Full Text] [Related]
55. Utility of flow cytometry screening before MRD testing in multiple myeloma. Panakkal V; Lakshman A; Shi M; Olteanu H; Horna P; Timm MM; Otteson GE; Baughn LB; Greipp PT; Gonsalves WI; Kapoor P; Gertz MA; Binder M; Buadi FK; Dispenzieri A; Rajkumar SV; Kumar SK; Jevremovic D Blood Cancer J; 2023 Apr; 13(1):55. PubMed ID: 37080968 [No Abstract] [Full Text] [Related]
56. High-risk multiple myeloma predicted by circulating plasma cells and its genetic characteristics. Xia Y; Shen N; Zhang R; Wu Y; Shi Q; Li J; Chen L; Xu M; Jin Y Front Oncol; 2023; 13():1083053. PubMed ID: 36845679 [TBL] [Abstract][Full Text] [Related]
57. Plasma cells arise from differentiation of clonal lymphocytes and secrete IgM in Waldenström macroglobulinemia. Lim JH; Wang JQ; Webb F; Saxena K; Enosi Tuipulotu D; Pandey A; Man SM; Talaulikar D iScience; 2022 Aug; 25(8):104856. PubMed ID: 35992066 [TBL] [Abstract][Full Text] [Related]
58. [Expression of CD45 in newly diagnosed multiple myeloma and the relationship with prognosis]. Shi J; Zhu ZM; Sun K; Lei PC; Liu ZW; Guo JM; Yang J; Zang YZ; Zhang Y Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):744-749. PubMed ID: 31648475 [No Abstract] [Full Text] [Related]
60. Multiple Myeloma Exemplifies a Model of Cancer Based on Tissue Disruption as the Initiator Event. Capp JP; Bataille R Front Oncol; 2018; 8():355. PubMed ID: 30250824 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]